De novo MET amplification promotes intrinsic resistance to first-generation EGFR tyrosine kinase inhibitors

Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer

(2018) Makoto Nishio et al.   Cancer Research and Treatment

De Novo MET Amplification in Chinese Patients With Non–Small-Cell Lung Cancer and Treatment Efficacy With Crizotinib: A Multicenter Retrospective Study

(2018) Zhengbo Song et al.   Clinical Lung Cancer

Targeting MET in Lung Cancer: Will Expectations Finally Be MET?

(2017) Alexander Drilon et al.   Journal of Thoracic Oncology

Cancer statistics, 2016

(2016) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment

(2016) Puyu Shi et al.   CANCER LETTERS

AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer

(2014) D. A. E. Cross et al.   Cancer Discovery

Lung Cancer Biomarkers: Present Status and Future Developments

(2013) Philip T. Cagle et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

(2011) L. V. Sequist et al.   Science Translational Medicine

An overview of the c-MET signaling pathway

(2011) Shawna Leslie Organ et al.   Therapeutic Advances in Medical Oncology

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

(2010) Makoto Maemondo et al.   NEW ENGLAND JOURNAL OF MEDICINE